India & Abbott Laboratories

India: India is a key country in the MSCI Asia Pacific Index region, which is witnessing rapid market growth due to increasing healthcare investments and expanding laboratory infrastructure.

Abbott Laboratories: As a major player in the CLIA market, Abbott Laboratories is strengthening its market position through innovation and strategic collaborations, with its ARCHITECT and Alinity i systems playing a major role in advancing high-throughput immunodiagnostic testing globally.

India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.

Abbott Laboratories: Abbott Laboratories is one of several Indian generic drugmakers poised to enter the market with lower-priced versions of semaglutide once Semaglutide loses patent exclusivity.